Marnonette Marallag1,2, Amitkumar Patel2,3, Myunghan Choi4, Mark N Wong5, Anil B Seetharam6,5. 1. Internal Medicine, Banner University Medical Center, Phoenix, AZ, U.S.A. 2. University of Arizona College of Medicine, Phoenix, AZ, U.S.A. 3. Gastroenterology, Banner University Medical Center, Phoenix, AZ, U.S.A. 4. Nursing and Health Care Innovation, Arizona State University, Tempe, AZ, U.S.A. 5. Transplant and Advanced Liver Disease Center, Banner University Medical Center, Phoenix, AZ, U.S.A. 6. University of Arizona College of Medicine, Phoenix, AZ, U.S.A. Anil.Seetharam@bannerhealth.com.
Abstract
BACKGROUND/AIM: The neutrophil-lymphocyte ratio (NLR) has gained attention as an index of inflammation in patients with chronic hepatitis B virus (HBV); however, changes with nucleoside analog therapy require investigation. PATIENTS AND METHODS: We carried out a retrospective study identifying monoinfected HBV patients initiated on therapy with NLR follow-up over 1 year. Biochemistries recorded at treatment initiation and 1 year included alanine aminotransferase (ALT), Model for End Stage Liver Disease (MELD) score, and NLR. RESULTS: A total of 67 patients were initiated on therapy and had baseline characteristics including e-antigen (eAg) (50, 74.6%) and cirrhosis (19, 28.4%). On subgroup analysis among those with HBV-associated cirrhosis, the NLR decreased over 1 year (3.08±0.39 vs. 1.77±0.18, p<0.001) as did MELD and ALT. Among the non-cirrhotic cohort, there was no difference in NLR (1.99±0.89 vs. 2.14±1.03, p=0.134) despite a decrease in ALT. CONCLUSION: Nucleoside analog therapy in HBV cirrhosis is associated with a decrease in NLR over 1 year that tracks with changes of established indices of inflammation/global hepatic function. Copyright
BACKGROUND/AIM: The neutrophil-lymphocyte ratio (NLR) has gained attention as an index of inflammation in patients with chronic hepatitis B virus (HBV); however, changes with nucleoside analog therapy require investigation. PATIENTS AND METHODS: We carried out a retrospective study identifying monoinfected HBVpatients initiated on therapy with NLR follow-up over 1 year. Biochemistries recorded at treatment initiation and 1 year included alanine aminotransferase (ALT), Model for End Stage Liver Disease (MELD) score, and NLR. RESULTS: A total of 67 patients were initiated on therapy and had baseline characteristics including e-antigen (eAg) (50, 74.6%) and cirrhosis (19, 28.4%). On subgroup analysis among those with HBV-associated cirrhosis, the NLR decreased over 1 year (3.08±0.39 vs. 1.77±0.18, p<0.001) as did MELD and ALT. Among the non-cirrhotic cohort, there was no difference in NLR (1.99±0.89 vs. 2.14±1.03, p=0.134) despite a decrease in ALT. CONCLUSION:Nucleoside analog therapy in HBV cirrhosis is associated with a decrease in NLR over 1 year that tracks with changes of established indices of inflammation/global hepatic function. Copyright
Authors: Henry Roberts; Deanna Kruszon-Moran; Kathleen N Ly; Elizabeth Hughes; Kashif Iqbal; Ruth B Jiles; Scott D Holmberg Journal: Hepatology Date: 2015-10-27 Impact factor: 17.425